Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Coverage With Evidence Development and Expedited Approvals: Policy Proposals For FDA and CMS

This article was originally published in RPM Report

Executive Summary

Based on stakeholder consultations, former FDA and CMS head Mark McClellan and former CMS official Sean Tunis present a potential upside for biopharma in broader use of Medicare coverage with evidence development. Pfizer executives participate in workshop on coordinating expedited drug approval, CED policies.

You may also be interested in...



The Value of Knowing: CMS Rejects Coverage of Lilly’s Amyvid – Except As Tool For Further Research

CMS is proposing to deny coverage of Lilly’s Alzheimer’s “rule-out” diagnostic Amyvid. The decision is important for biopharma manufacturers for several reasons, both as a demonstration that the agency really will refuse to pay for FDA approved drugs—and for how CMS thinks it can actually use its authority to encourage research on effective AD therapies.

Accelerated Approval Expansion Proposals Pending, But One Needs An Overhaul

ULTRA bill will need changes to gain the support of influential patient group. Meanwhile, BIO is circulating a proposal to make changes to existing regulations.

CMS Sets The Stage For New Medicare "Coverage With Evidence Development" Guidance

A rarely-used tool for gathering data on medical technologies will get a fresh look as the agency solicits public comment on how to make CED a more meaningful and effective part of its coverage decision-making process.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS080966

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel